佐思市场研究报告网
最新报告 网站地图 联系我们 登陆 首页
研究报告
 报告定制
 资料下载
 竞争情报
 行业情报
 企业研究
 佐思软件
 佐思年鉴
 English
报告购买流程
定购方法
① 注册订购：
点击在线订购进行报告订购
我们的服务人员将在24小时内与您联系。

② 电话订购：
拔打电话：

北京：010-51266615
    010-82863480/1/2/5
24小时：13436696826
传真:010-82863486

上海：021-64871266
             021-64872612
24小时：13524982235
传真:021-64872324

签订协议
可从网上下载报告订购表或由我们传真报告订购表或订购协议。
传真:010-82863486

付款方式
① 通过银行转帐的形式支付报告购买款项
② 我们收到款项后，24小时内快递报告或者发送报告邮件

③ 款项到帐后快递发票
银行电汇：
北京：
开户行：
上海浦东发展银行北京知春路支行
帐号：91170154740001300
户名： 北京佐思信息咨询有限责任公司
联系人：张小姐

研究报告导航
[TMT产业]
通信业 电子元器件 传媒业
计算机 软件行业 互联网
[医药产业]
化学原料药及化学制剂
中药业 生物制药业
医药综合及医疗器械行业
[化学工业]
化肥和农药 化学纤维 石化
化工综合 日用及有机化工
塑料业
[能源材料]
能源电力 煤炭 有色金属
钢铁 玻璃 新能源新材料
[公共服务]
金融银行 百货零售 旅游 文体娱乐 宏观经济 外贸
[交通运输]
汽车及相关行业 民航业
公路及铁路运输
港口与物流
[日用产品]
家电家居 纺织业
服装业 纸业
[工业设备]
输配电及控制设备
锅炉及原动机 金属制品
专用设备制造 通用设备
[食品其它]
食品饮料 制酒
农林牧渔业 其它
[房产建筑]
房地产 建筑业 水泥
您的位置：佐思研究报告和竞争情报网>>研究报告交易平台>>医药产业>>生物制药业
心脏标记诊断测试市场研究报告——Cardiac Marker Diagnostic Testing Markets
字体【大 中 小】
纸介版价格：美元/篇 字数：万字
电子版价格：3400美元/篇 页数：页
纸介版+电子版价格：美元 图表数：个
完成日期：2008-05-16
关键字： 心脏标记|Cardiac Marker
 联系方式： 北京：010-51266615 010-82863480/1/2/5 传真:010-82863486  上海：021-64871266 021-64872612 传真:021-64872324    [在线订购]  

发布时间：2008年5月1日

摘要：

The purpose of this TriMark Publications report is to describe the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing. This study examines clinical measurement devices and their reagents and supplies as used in hospitals, clinics and doctor's offices. This examination is arranged to provide the reader with an overview of the outstanding diagnostic test market segments of cardiac care, with evidence that these segments are poised for high future growth. An overview of the diagnostic testing cardiac marker market is presented with the latest information regarding emerging new products and industry trends. It will not only quantify but also qualify the cardiac marker market segments as an area of research, product development and investment. Forecasts of the cardiac marker market and an analysis of products in the worldwide diagnostics market will provide a basis for understanding the significance of past developments and future possibilities within this diagnostic category.



正文目录：

Table of Contents:

  1. 1. Overview 6
  2. 1.1 Statement of Report 6
  3. 1.2 Objectives of This Report 6
  4. 1.3 Scope of This Report 8
  5. 1.4 Methodology 8
  6. 1.5 Executive Summary 8
  8. 2. Introduction 11
  9. 2.1 Global Diagnostic Products Industry 11
  10. 2.2 Barriers to Entry 14
  11. 2.3 Company Evaluation Overview 15
  12. 2.4 Market Outlook 16
  13. 2.5 Technologies and Products that are the Most Successful in the New IVD Environment 16
  15. 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 18
  16. 3.1 Global Cardiac Marker Diagnostic Testing Markets 18
  17. 3.1.1 Clinical Utility of Cardiac Markers 22
  18. 3.1.2 Market Drivers in the Cardiac Marker Diagnostics Testing Sector 24
  19. 3.1.3 Market Restraints in Cardiac Marker Testing Segment 24
  20. 3.1.4 Principal Market Segments for Cardiac Marker Testing 24
  21. 3.1.5 Key Players in the Cardiac Marker Diagnostics Testing Segment 25
  22. 3.1.6 Cardiac Marker Testing Sector Analysis 26
  23. 3.1.7 Cardiac Marker Market Share 26
  24. 3.2 U.S. Cardiac Marker Testing Market 26
  25. 3.2.1 Market Overview 26
  26. 3.2.2 Diagnostic Test Categories 27
  27. 3.2.3 U.S. Hospital POC Cardiac Markers 28
  28. 3.3 European Cardiac Marker Diagnostic Test Market 29
  29. 3.3.1 German Diagnostic Markets 32
  30. 3.3.2 U.K. Diagnostic Testing Market 33
  31. 3.3.2.1 U.K. Market Statistics 33
  32. 3.3.2.2 U.K. Competitive Analysis 34
  33. 3.3.2.3 U.K. Market Access 35
  34. 3.3.3 Italy 35
  35. 3.3.4 France 36
  36. 3.3.5 Spain 36
  37. 3.3.6 Belgium 36
  38. 3.3.7 Switzerland 37
  39. 3.3.8 Barriers to Entry to European Market 37
  40. 3.4 Japanese Diagnostic Testing Market 37
  41. 3.5 Chinese Diagnostic Testing Market 37
  42. 3.6 Canadian Diagnostic Market 40
  43. 3.7 Cardiac Marker Testing Individual Markets 40
  44. 3.7.1 Clinical Overview 40
  45. 3.7.2 Cardiac Acute Disease Markers 41
  46. 3.7.3 Market Overview 42
  47. 3.7.3.1 AMI and Troponins 44
  48. 3.7.3.2 Market Size and Growth Projections 47
  49. 3.7.3.3 Clinical Use of Cardiac Troponins 48
  50. 3.7.3.4 TnI and TnT Market Drivers 51
  51. 3.7.3.5 TnI and TnT Market Restraints 51
  52. 3.7.3.6 New Tests for Troponin 52
  53. 3.7.4 CK-MB and Cardiac Enzymes 52
  54. 3.7.4.1 CK Enzymes 52
  55. 3.7.4.2 Market Size and Growth Projections 53
  56. 3.7.4.3 CK-MB: Market Drivers 54
  57. 3.7.4.4 CK-MB: Market Restraints 54
  58. 3.7.5 Myoglobin 54
  59. 3.7.5.1 Market Size and Growth Projections 54
  60. 3.7.5.2 Clinical Use of Myoglobin 55
  61. 3.7.5.3 Myoglobin Market Drivers 56
  62. 3.7.5.4 Myoglobin Market Restraints 56
  63. 3.7.6 BNP 56
  64. 3.7.6.1 Market Overview 56
  65. 3.7.6.2 Market Size and Growth Projections 58
  66. 3.7.6.3 Commercial Assays for BNP and NT-proBNP 58
  67. 3.7.6.4 Competitive Landscape 60
  68. 3.7.6.5 BNP Test Market Share 60
  69. 3.7.6.6 Clinical Applications of BNP 62
  70. 3.7.6.7 BNP Market Drivers 64
  71. 3.7.6.8 BNP Market Restraints 65
  72. 3.7.7 Albumin 65
  73. 3.7.7.1 Intact Albumin 65
  74. 3.7.7.2 Albumin Cobalt Binding Test 65
  75. 3.7.7.3 Ischemic Modified Albumin 66
  76. 3.7.7.4 Microalbuminuria 68
  77. 3.7.8 Key Players in Cardiac Markers 68
  78. 3.7.9 Cardiac Marker Controls 77
  79. 3.7.10 Evaluation of Cardiac Markers 77
  80. 3.7.11 Cardiac Markers Use in Clinical Decisions 78
  81. 3.7.12 Status of Cardiac Markers in the ER 78
  82. 3.7.13 Cardiac Markers in Renal Failure 78
  83. 3.7.14 Troponins in Non-Ischemic Heart Disease 79
  84. 3.7.15 Market Restraints 79
  85. 3.7.16 Market Drivers 80
  86. 3.7.17 Cardiac Panels 80
  87. 3.7.18 POC Cardiac Markers 80
  88. 3.7.18.1 Market Size and Growth Rate 80
  89. 3.7.18.2 Market Restraints 81
  90. 3.7.18.3 The Next Wave 82
  92. 4. Cardiovascular Disease Markers 86
  93. 4.1 Cholesterol, HDL and LDL 86
  94. 4.1.1 Cholesterol Testing Market Forecasts 87
  95. 4.1.2 Cholesterol Market Growth Drivers 87
  96. 4.1.3 Market Outlook: U.S. Market Analysis 87
  97. 4.1.4 Trends and Issues 88
  98. 4.1.5 Key Players in the Cholesterol OTC Kit Market 88
  99. 4.2 Homocysteine 88
  100. 4.3 Fibrinogen 89
  101. 4.4 C-Reactive Protein 89
  102. 4.5 Lipoprotein Fractions 91
  103. 4.6 Pulmonary Embolism (D-Dimer Test) 92
  104. 4.7 Oxidized LDL and HDL 92
  105. 4.8 Stroke 92
  107. 5. Cardiac Marker Testing Development Issues 94
  108. 5.1 Genetic Testing and Personalized Medicine 94
  109. 5.2 Preventive Medicine 94
  110. 5.3 Patient Safety and Quality Measures 94
  111. 5.4 Reimbursement 95
  112. 5.5 Cardiovascular 97
  113. 5.6 Screening for Diabetes 97
  114. 5.7 Other Reimbursement Concerns 98
  115. 5.7.1 Reimbursement for Routine Venipuncture 98
  116. 5.7.2 Japanese Reimbursements for Medical Devices 98
  117. 5.8 CPT Test Codes and Payment Amounts 98
  118. 5.9 Rapid Near-Patient Testing in Hospitals 99
  119. 5.10 Satellite Facilities 99
  120. 5.11 Regionalization of Laboratory Care 100
  121. 5.12 Requirements for POCT 101
  122. 5.12.1 Benefits of POCT 102
  123. 5.12.2 Turnaround Time for POCT 103
  124. 5.13 Clinical Laboratory Improvement Amendments (CLIA) 103
  125. 5.14 Quality Assurance Issues 104
  126. 5.15 Political Control 105
  127. 5.16 Regulatory Requirements 105
  128. 5.17 Recordkeeping and Data Management 105
  129. 5.17.1 Effectiveness of Clinical Outcomes 105
  131. 6. Business Trends in the Industry 106
  132. 6.1 Sector Consolidation 106
  133. 6.2 Diagnostic Testing Growth Trends 106
  134. 6.3 Acquisition, License Agreements, Internal Development and Partnerships 108
  135. 6.4 Product Testing Depth in Cardiac Marker Testing 111
  136. 6.5 Government Regulation 111
  137. 6.5.1 U.S. Regulation 111
  138. 6.5.1.1 Importing Medical Devices into the U.S. 112
  139. 6.5.1.2 Exporting Medical Devices from the U.S. 113
  140. 6.5.2 U.K. Regulations 113
  141. 6.5.3 E.U. Regulations 114
  142. 6.5.4 Japanese Regulations 115
  143. 6.5.5 Chinese Regulations 116
  144. 6.6 Barriers to Growth 117
  145. 6.7 Drivers of Growth 117
  146. 6.8 Product Launches and Developments 117
  148. 7. Important Technology Trends 119
  149. 7.1 Trends in Cardiac Marker Diagnostic Testing 119
  150. 7.1.1 Fatty Acid Binding Protein 120
  151. 7.1.2 Glycogen Phosphorylase Isoenzyme BB 120
  152. 7.1.3 S-100 Protein 120
  153. 7.1.4 Cobalt-Binding Albumin 120
  154. 7.1.5 Myosin Light Chains 121
  155. 7.2 Cardiac Biomarker Research 121
  156. 7.2.1 Myeloperoxidase 121
  157. 7.2.2 Glutathione Peroxidase 122
  158. 7.2.3 Antioxidant Biomarkers 122
  159. 7.2.4 Oxidative Biomarkers 122
  160. 7.2.5 Inflammatory Biomarkers 123
  161. 7.2.6 Nitrosative Biomarkers 123
  162. 7.2.7 Hemostatic Biomarkers 124
  163. 7.3 Potential Stroke Markers 124
  164. 7.3.1 Pharmacogenomics: Cardiovascular Drugs and Proteomic Markers 125
  165. 7.3.2 Cardiac Proteomics 125
  166. 7.3.3 Drivers for Cardiovascular Proteomic Markers 125
  167. 7.3.4 Barriers to Cardiovascular Proteomic Markers 126
  168. 7.4 Future Developments for Cardiovascular Markers 126
  169. 7.5 Research Questions 126
  170. 7.5.1 Roche's Biomarker Strategy 129
  171. 7.5.2 Biomarkers for Unstable Angina 130
  172. 7.6 Lp-PLA2 130
  173. 7.7 Urotensin 131
  175. 8. Company Profiles 132
  176. 8.1 Abbott Laboratories 132
  177. 8.2 Ani Biotech 136
  178. 8.3 Axis-Shield 137
  179. 8.4 Bayer Corporation 138
  180. 8.5 Beckman Coulter 139
  181. 8.6 Biosite, Inc. (now a brand of Inverness Medical Innovations) 141
  182. 8.7 Inverness Medical Innovations 144
  183. 8.8 Johnson & Johnson 146
  184. 8.9 LifeSign 146
  185. 8.10 Olympus America 146
  186. 8.11 PreMD, Inc. 147
  187. 8.12 Randox Laboratories 147
  188. 8.13 Response Biomedical 147
  189. 8.14 Roche Diagnostics 148
  190. 8.16 Sierra Resources International 152
  191. 8.17 Spectral Diagnostics, Inc. 152
  194. LIST OF FIGURES
  196. Figure 2.1: Lab Industry Market Share 13
  197. Figure 2.2: Market Share of Major Lab Testing Segments 14
  199. 图表目录：
  201. LIST OF TABLES
  203. Table 2.1: World Population and Growth, 2000-2024 11
  204. Table 2.2: Worldwide Market Share IVD Companies 12
  205. Table 2.3: U.S. In Vitro Central Lab Diagnostic Testing, 2001-2007 13
  206. Table 2.4: Worldwide Near-Patient Diagnostic Testing, 2001-2007 13
  207. Table 3.1: Cardiac Marker Markets by Country, 2002-2010 18
  208. Table 3.2: Total Global Cardiac Marker Market, 2002-2010 18
  209. Table 3.3: Overall IVD Testing Market Worldwide, 2007 20
  210. Table 3.4: Worldwide Distribution of IVD Testing, 2007 20
  211. Table 3.5: Top 12 Countries for IVD Testing Markets, 2007 20
  212. Table 3.6: Eight Largest Diagnostic Companies Worldwide, 2007 21
  213. Table 3.7: Cardiac Markers 23
  214. Table 3.8: Market Share of Cardiac Marker Segment 26
  215. Table 3.9: U.S. Cardiac Marker Market, 2001-2010 27
  216. Table 3.10: U.S. Cardiac Marker Diagnostic Testing Market Segments, 2007 27
  217. Table 3.11: U.S. POC Cardiac Marker Sales, 2001-2010 28
  218. Table 3.12: The Cardiac Marker Market for Diagnostic Testing in Europe, 2001-2010 30
  219. Table 3.13: Regional Comparison of Healthcare and IVD Expenditures 31
  220. Table 3.14: German Diagnostics Products Market Sales, 1997-2008 32
  221. Table 3.15: The German Cardiac Marker Test Market, 2000-2010 32
  222. Table 3.16: U.K. Cardiac Marker Market, 2001-2010 34
  223. Table 3.17: Major U.K. IVD Manufacturers 34
  224. Table 3.18: U.S. IVD Manufacturers Doing Business in the U.K. 34
  225. Table 3.19: Other European Companies that Manufacture IVD Products in the U.K. 35
  226. Table 3.20: Italian Cardiac Marker Market, 2001-2010 35
  227. Table 3.21: French Cardiac Marker Market, 2001-2010 36
  228. Table 3.22: Spanish Cardiac Marker Market, 2001-2010 36
  229. Table 3.23: Japanese Cardiac Marker Diagnostic Testing Market, 2001-2010 37
  230. Table 3.24: Chinese Diagnostics Products Market, 2000-2010 38
  231. Table 3.25: ER Admissions in the U.S., 1997-2005 43
  232. Table 3.26: Common Causes of Chest Pain 43
  233. Table 3.27: Rate of Inappropriate Discharge from the ER for Patients with AMI 44
  234. Table 3.28: Continuing Analytical Issues for Implementation of Cardiac Troponin 46
  235. Table 3.29: Global Cardiac Troponin Marker Market, 2001-2010 47
  236. Table 3.30: U.S. Cardiac Troponin Marker Market, 2001-2010 48
  237. Table 3.31: Trends in U.S. Sales of POC Cardiac Marker Tests, 1998-2007 48
  238. Table 3.32: World Revenue from CK-MB Markets, 2001-2010 53
  239. Table 3.33: U.S. Revenue from CK-MB Markets, 2001-2010 53
  240. Table 3.34: World Myoglobin Market Revenues, 2001-2010 54
  241. Table 3.35: U.S. Myoglobin Market Revenues, 2001-2010 55
  242. Table 3.36: BNP Clinical Characteristics 57
  243. Table 3.37: Worldwide Sales of BNP Diagnostic Tests, 2004-2010 58
  244. Table 3.38: U.S. Sales of BNP Diagnostic Tests, 2004-2010 58
  245. Table 3.39: Commercial BNP Assays in the U.S. 61
  246. Table 3.40: Market Share of BNP Assays in the U.S. 61
  247. Table 3.41: Market Share of NT-proBNP Assays in the U.S. 61
  248. Table 3.42: Siemens Healthcare Diagnostics Cardiac Marker Assays 76
  249. Table 3.43: Cardiac Markers: Sampling Frequency 77
  250. Table 3.44: Cardiac Marker Products by LifeSign 80
  251. Table 4.1: HDL Levels in Adults 86
  252. Table 4.2: LDL Levels in Adults 87
  253. Table 4.3: LDL Screening Management Rates-Percent of Patient Population 87
  254. Table 4.4: Number of U.S. Cholesterol Tests, 2000-2010 88
  255. Table 4.5: World CRP Market Revenue, 2001-2010 90
  256. Table 4.6: U.S. CRP Market Revenue, 2001-2010 91
  257. Table 4.7: Clinical Characteristics of D-Dimer 92
  258. Table 5.1: POCT in Two Hospitals Cost Analysis with Labor Included 102
  259. Table 5.2: Cost Analysis for Glucose Testing: POCT vs. Central Lab 102
  260. Table 5.3: Financial Comparison for Moderate and Waived CLIA Labs 103
  261. Table 5.4: POCT Clinical Outcomes in AMI 105
  262. Table 7.1: Oxidative Biomarker Research Assay Market Size 123
  263. Table 7.2: Non-Lipid Markers of CVD 127
  264. Table 8.1: Products Marketed by Abbott in the Diagnostic Market 135
  265. Table 8.2: Products Marketed by Biosite in the Diagnostic Market 143

如果这份报告还不能满足您的需求，或者您对这份报告还有什么意见或者建议，请您填写以下反馈信息。
百度主题推广
关于我们 | 报告购买帮助 | 定制服务 | 关于佐思软件 | 会员服务申请 | 常见问题 | 版权申明 | 友情链接 | 联系我们
2005-2007 OKOKOK.com.cn All rights reserved. 佐思信息 版权所有 京ICP证041200号
北京：010-51266615 010-82863480/1/2/5 传真:010-82863486 上海：021-64871266 021-64872612 传真:021-64872324
Email: 地址：北京市海淀区五道口华清商务会馆906D（100083）


PDF阅读软件